Farnesoid x receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet

Journal of Pharmacology and Experimental Therapeutics

Volumn 328, Issue 1, 2009, Pages 116-122

  Kong, Bo ^a   Luyendyk, James P ^a   Tawfik, Ossama ^a   Guo, Grace L ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; FARNESOID X RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN RECEPTOR; PROCOLLAGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; CELL RECEPTOR; DNA BINDING PROTEIN; FARNESOID X-ACTIVATED RECEPTOR; LIPID; PRIMER DNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; INFLAMMATION; KNOCKOUT MOUSE; LIPID BLOOD LEVEL; LIPID DIET; LIPID METABOLISM; LIVER FIBROSIS; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WEIGHT GAIN; ANIMAL; ANIMAL FOOD; CROSS BREEDING; FAT INTAKE; FATTY LIVER; FEMALE; GENETICS; GENOTYPE; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION;

ANIMAL FEED; ANIMALS; CROSSES, GENETIC; DIETARY FATS; DNA PRIMERS; DNA-BINDING PROTEINS; FATTY LIVER; FEMALE; GENOTYPE; INFLAMMATION; LIPIDS; MALE; MICE; MICE, KNOCKOUT; POLYMERASE CHAIN REACTION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, LDL; TRANSCRIPTION FACTORS;

EID: 59149106502     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.144600     Document Type: Article

References (49)

1. Anstee QM and Goldin RD (2006) Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 87:1-16.
2. Aranha MM, Cortez-Pinto H, Costa A, da Silva IB, Camilo ME, de Moura MC, and Rodrigues CM (2008) Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol 20:519-525.
3. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Alemán JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Stephanopoulos G, et al. (2008) Hepatic Insulin Resistance Is Sufficient to Produce Dyslipidemia and Susceptibility to Atherosclerosis. Cell Metab 7:125-134.
4. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, et al. (2002) NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35:373-379.
5. DeLeve LD, Wang X, Kanel GC, Atkinson R, and McCuskey RS (2007) Prevention of hepatic fibrosis in a murine model of metabolic syndrome with non-alcoholic steatohepatitis (NASH). Hepatology 46:761A-762A.
6. Deng QG, She H, Cheng JH, French SW, Koop DR, Xiong S, and Tsukamoto H (2005) Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 42:905-914.
7. Dent P, Fang Y, Gupta S, Studer E, Mitchell C, Spiegel S, and Hylemon PB (2005) Conjugated bile acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes. Hepatology 42:1291-1299.
8. Farrell GC and Larter CZ (2006) Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology 43:S99-S112.
9. Goldstein JL and Brown MS (1982) The LDL receptor defect in familial hypercholesterolemia: implications for pathogenesis and therapy. Med Clin North Am 66:335-362.
10. Guo GL, Lambert G, Negishi M, Ward JM, Brewer HB Jr, Kliewer SA, Gonzalez FJ, and Sinal CJ (2003) Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J Biol Chem 278:45062-45071.
11. Guo GL, Santamarina-Fojo S, Akiyama TE, Amar MJ, Paigen BJ, Brewer B Jr, and Gonzalez FJ (2006) Effects of FXR in foam-cell formation and atherosclerosis development. Biochim Biophys Acta 1761:1401-1409.
12. Gyamfi MA, Damjanov I, French S, and Wan YJ (2008) The pathogenesis of ethanol versus methionine and choline deficient diet-induced liver injury. Biochem Pharmacol 75:981-995.
13. Hanniman EA, Lambert G, McCarthy TC, and Sinal CJ (2005) Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J Lipid Res 46:2595-2604.
14. Hubscher SG (2006) Histological assessment of non-alcoholic fatty liver disease. Histopathology 49:450-465.
15. Ishibashi S, Goldstein JL, Brown MS, Herz J, and Burns DK (1994) Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest 93:1885-1893.
16. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, and Lemasters JJ (2002) Mechanisms of hepatotoxicity. Toxicol Sci 65:166-176.
17. James OF and Day CP (1998) Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 29:495-501.
18. Kast HR, Nguyen CM, Sinal CJ, Jones SA, Laffitte BA, Reue K, Gonzalez FJ, Willson TM, and Edwards PA (2001) Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol 15:1720-1728.
19. Keitel V, Donner M, Winandy S, Kubitz R, and Haussinger D (2008) Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun 372:78-84.
20. Keitel V, Reinehr R, Gatsios P, Rupprecht C, Görg B, Selbach O, Häussinger D, and Kubitz R (2007) The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology 45:695-704.
21. Kim ND, Moon JO, Slitt AL, and Copple BL (2006) Early growth response factor-1 is critical for cholestatic liver injury. Toxicol Sci 90:586-595.
22. KleinerDE,BruntEM,VanNattaM,BehlingC,ContosMJ,CummingsOW,Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-1321.
23. Lambert G, Amar MJ, Guo G, Brewer HB Jr, Gonzalez FJ, and Sinal CJ (2003) The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 278:2563-2570.
24. Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, Ponomarenko A, and DeCarli LM (2004) Model of nonalcoholic steatohepatitis. Am J Clin Nutr 79:502-509.
25. Liu Y, Binz J, Numerick MJ, Dennis S, Luo G, Desai B, MacKenzie KI, Mansfield TA, Kliewer SA, Goodwin B, et al. (2003) Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 112:1678-1687.
26. Loria P, Lonardo A, Bellentani S, Day CP, Marchesini G, and Carulli N (2007) Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis 17:684-698.
27. Ma K, Saha PK, Chan L, and Moore DD (2006) Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 116:1102-1109.
28. Ma KL, Ruan XZ, Powis SH, Chen Y, Moorhead JF, and Varghese Z (2008) Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. Hepatology 48:770-781.
29. Maloney PR, Parks DJ, Haffner CD, Fivush AM, Chandra G, Plunket KD, Creech KL, Moore LB, Wilson JG, Lewis MC, et al. (2000) Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 43:2971-2974.
30. Marzolini C, Tirona RG, Gervasini G, Poonkuzhali B, Assem M, Lee W, Leake BF, Schuetz JD, Schuetz EG, and Kim RB (2007) A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol Endocrinol 21:1769-1780.
31. McMahon SB and MonroeJG(1996) The roleofearlygrowthresponsegene1 (egr-1) in regulation of the immune response. J Leukoc Biol 60:159-166.
32. Musso G, Cassader M, Gambino R, Durazzo M, and Pagano G (2006) Association between postprandial LDL conjugated dienes and the severity of liver fibrosis in NASH. Hepatology 43:1169-1170.
33. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, et al. (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science 284:1365-1368.
34. Qiao L, Han SI, Fang Y, Park JS, Gupta S, Gilfor D, Amorino G, Valerie K, Sealy L, Engelhardt JF, et al. (2003) Bile acid regulation of C/EBPbeta, CREB, and c-Jun function, via the extracellular signal-regulated kinase and c-Jun NH2-terminal kinase pathways, modulates the apoptotic response of hepatocytes. Mol Cell Biol 23:3052-3066.
35. Rao YP, Studer EJ, Stravitz RT, Gupta S, Qiao L, Dent P, and Hylemon PB (2002) Activation of the Raf-1/MEK/ERK cascade by bile acids occurs via the epidermal growth factor receptor in primary rat hepatocytes. Hepatology 35:307-314.
36. Rector RS, Thyfault JP, Wei Y, and Ibdah JA (2008) Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 14:185-192.
37. Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ, and Diamant M (2007a) Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 191:391-396.
38. Schindhelm RK, Heine RJ, and Diamant M (2007b) Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30:e94-e95.
39. Shiri-Sverdlov R, Wouters K, van Gorp PJ, Gijbels MJ, Noel B, Buffat L, Staels B, Maeda N, van Bilsen M, and Hofker MH (2006) Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J Hepatol 44:732-741.
40. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, and Gonzalez FJ (2000) Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102:731-744.
41. Singh DK, Sakhuja P, Malhotra V, Gondal R, and Sarin SK (2008) Independent Predictors of Steatohepatitis and Fibrosis in Asian Indian Patients with Non-Alcoholic Steatohepatitis. Digest Dis Sci 53:1967-1976.
42. Sorrentino P, Tarantino G, Perrella A, Micheli P, Perrella O, and Conca P (2005) A clinical-morphological study on cholestatic presentation of nonalcoholic fatty liver disease. Dig Dis Sci 50:1130-1135.
43. Tous M, Ferré N, Camps J, Riu F, and Joven J (2005) Feeding apolipoprotein E-knockout mice with cholesterol and fat enriched diets may be a model of nonalcoholic steatohepatitis. Molecular and Cellular Biochemistry 268:53-58.
44. Urizar NL, Dowhan DH, and Moore DD (2000) The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression. J Biol Chem 275:39313-39317.
45. Wang H, Chen J, Hollister K, Sowers LC, and Forman BM (1999) Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 3:543-553.
46. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, Moore DD, and Auwerx J (2004) Bile acids lower triglyceride levels via a pathway involving FXR, SHP, andSREBP-1c. J Clin Invest 113:1408-1418.
47. Weltman MD, Farrell GC, and Liddle C (1996) Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gas-troenterology 111:1645-1653.
48. Wouters K, van Gorp PJ, Bieghs V, Gijbels MJ, Duimel H, Lütjohann D, Kerksiek A, van Kruchten R, Maeda N, Staels B, et al. (2008) Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 48:474-486.
49. Yoshimatsu M, Terasaki Y, Sakashita N, Kiyota E, Sato H, van der Laan LJ, and Takeya M (2004) Induction of macrophage scavenger receptor MARCO in nonalcoholic steatohepatitis indicates possible involvement of endotoxin in its pathogenic process. Int J Exp Pathol 85:335-343.